RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PYC Therapeutics - Stock

PYC Therapeutics Debt 2024

PYC Therapeutics Debt

-15.26 AUD

Ticker

PYC.AX

ISIN

AU000000PYC7

WKN

A0D8ZY

In 2024, PYC Therapeutics's total debt was -15.26 AUD, a -45.84% change from the -28.17 AUD total debt recorded in the previous year.

PYC Therapeutics Aktienanalyse

What does PYC Therapeutics do?

PYC Therapeutics Ltd is a biopharmaceutical company based in Sydney, Australia. The company was founded in 2017 by experienced pharmaceutical and biotech managers and currently employs over 40 employees. The history of PYC Therapeutics began with the development of a novel therapy platform called "PCytTM", which is based on the use of artificial proteins. These proteins can enhance the uptake of drugs into cells, thereby increasing the effectiveness of various medications. In 2018, PYC Therapeutics achieved a significant milestone by being included in the prestigious Accelerating Commercialisation program of the Australian government. PYC Therapeutics' business model focuses on the research and development of innovative cancer therapies and rare genetic diseases. The company strives to focus on diseases for which there is currently no effective treatment. This is intended to be achieved through partnerships, licensing, and potentially through the acquisition of companies and technologies. PYC Therapeutics shapes its processes through collaboration with experts in the fields of medicine, pharmacy, biotechnology, and chemistry. The divisions of PYC Therapeutics can be divided into the following areas of activity: drug development, platform technology, partnerships, and research and development. Under drug development, PYC Therapeutics understands the actual production of new cancer therapeutics and medications for the treatment of rare genetic diseases. The company relies on its internal research and also utilizes in-licensed technologies and acquisitions to develop novel drugs. Platform technology is a key success factor for PYC Therapeutics. The company has developed a highly effective method with PCytTM to optimize drug transport. This can significantly enhance the efficacy of medications. This technology has the potential to revolutionize the treatment of many diseases. Partnerships are an important part of PYC Therapeutics' business model. The company focuses on long-term collaborations with large pharmaceutical and biotech companies. This cooperation is intended to accelerate the development, approval, and commercialization of new medications. Research and development form the core of PYC Therapeutics' business model. The company invests significantly in the exploration of new therapeutics for cancer and rare genetic diseases. Since its inception, the company has continuously expanded its development platform and has become a key player in the industry. One of PYC Therapeutics' most important pipeline products is "PYC-06". PYC-06 is a medication developed for the treatment of acute myeloid leukemia (AML). The therapy aims to enhance the potential of chemotherapeutics by using PCytTM. The initial results of clinical studies show very promising results. Overall, PYC Therapeutics is an important player in the field of innovative cancer care and the treatment of rare genetic diseases. The company has a strong pipeline of novel therapeutics based on its PCytTM technology. PYC Therapeutics strives to improve the treatment of cancer and rare diseases and achieve a better quality of life for patients. The business model of PYC Therapeutics focuses on partnerships, innovative developments, and scientific research that contribute to advancing the industry. PYC Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding PYC Therapeutics's Debt Structure

PYC Therapeutics's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing PYC Therapeutics's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to PYC Therapeutics’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in PYC Therapeutics’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about PYC Therapeutics Stock

What is the debt of PYC Therapeutics this year?

PYC Therapeutics has a debt level of -15.26 AUD this year.

What was the debt of PYC Therapeutics compared to the previous year?

The debt of PYC Therapeutics has increased by -45.84% compared to the previous year dropped.

What are the consequences of high debt for investors in PYC Therapeutics?

High debt can pose a risk for investors of PYC Therapeutics, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of PYC Therapeutics?

Low debt means that PYC Therapeutics has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from PYC Therapeutics affect the company?

An increase in debt of PYC Therapeutics can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of PYC Therapeutics affect the company?

A reduction in debt of PYC Therapeutics can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of PYC Therapeutics?

Some factors that can influence the debt of PYC Therapeutics include investments, acquisitions, operating costs, and revenue development.

Why are the debts of PYC Therapeutics so important for investors?

The debts of PYC Therapeutics are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can PYC Therapeutics take to change the debt?

To change the debt, PYC Therapeutics can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does PYC Therapeutics pay?

Over the past 12 months, PYC Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, PYC Therapeutics is expected to pay a dividend of 0 AUD.

What is the dividend yield of PYC Therapeutics?

The current dividend yield of PYC Therapeutics is .

When does PYC Therapeutics pay dividends?

PYC Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of PYC Therapeutics?

PYC Therapeutics paid dividends every year for the past 0 years.

What is the dividend of PYC Therapeutics?

For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.

In which sector is PYC Therapeutics located?

PYC Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von PYC Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PYC Therapeutics from 7/2/2024 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 7/2/2024.

When did PYC Therapeutics pay the last dividend?

The last dividend was paid out on 7/2/2024.

What was the dividend of PYC Therapeutics in the year 2023?

In the year 2023, PYC Therapeutics distributed 0 AUD as dividends.

In which currency does PYC Therapeutics pay out the dividend?

The dividends of PYC Therapeutics are distributed in AUD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PYC Therapeutics

Our stock analysis for PYC Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PYC Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.